Javier Pérez Gisbert-rekin lankidetzan egindako argitalpenak (7)

2024

  1. Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 5, pp. 604-612

  2. Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU

    Digestive and Liver Disease, Vol. 56, Núm. 11, pp. 1845-1853

2022

  1. Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)

    Clinical Gastroenterology and Hepatology, Vol. 20, Núm. 10, pp. 2243-2257

  2. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2019

  1. Immunomodulatory Therapy Does Not Increase the Risk of Cancer in Persons With Inflammatory Bowel Disease and a History of Extracolonic Cancers

    The American journal of gastroenterology, Vol. 114, Núm. 5, pp. 771-776

  2. Increased risk of thiopurine-related adverse events in elderly patients with IBD

    Alimentary Pharmacology and Therapeutics, Vol. 50, Núm. 7, pp. 780-788

2012

  1. Accuracy of urea breath test performed immediately after emergency endoscopy in peptic ulcer bleeding

    Digestive Diseases and Sciences, Vol. 57, Núm. 7, pp. 1880-1886